Hurum Valuation

Is A353190 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A353190 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A353190's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A353190's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A353190?

Key metric: As A353190 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A353190. This is calculated by dividing A353190's market cap by their current earnings.
What is A353190's PE Ratio?
PE Ratio	23.8x
Earnings	₩1.20b
Market Cap	₩28.59b

A353190 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.4x
Enterprise Value/EBITDA	10.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A353190's PE Ratio compare to its peers?

The above table shows the PE ratio for A353190 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	14.8x
A318010 Pharmsville	36.6x	n/a	₩33.8b
A900120 CXI Healthcare Technology Group	0.7x	n/a	₩21.9b
A263920 HuM&C	6.7x	n/a	₩48.6b
A277410 INSAN	15x	n/a	₩49.5b
A353190 Hurum	23.8x	n/a	₩28.6b

Price-To-Earnings vs Peers: A353190 is expensive based on its Price-To-Earnings Ratio (23.8x) compared to the peer average (14.8x).

Price to Earnings Ratio vs Industry

How does A353190's PE Ratio compare vs other companies in the KR Personal Products Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A900120 CXI Healthcare Technology Group	0.7x	n/a	US$15.71m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A353190 is expensive based on its Price-To-Earnings Ratio (23.8x) compared to the KR Personal Products industry average (15.9x).

Price to Earnings Ratio vs Fair Ratio

What is A353190's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A353190 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	23.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A353190's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

NeoPharm

₩185.2b

Engages in the manufacturing and sale of skin care products in South Korea.

A092730

₩11,840.00

-9.0%

5.2%

NOVAREXLtd

₩133.5b

Manufactures, wholesales, and retails health and functional foods in South Korea and internationally.

A194700

₩7,540.00

-0.8%

-32.2%

HuM&C

₩48.6b

Engages in the manufacture and sale of various types of makeup products in South Korea and internationally.

A263920

₩991.00

0.7%

-16.1%